IFNγ secretion following stimulation with total tumor peptides from autologous human tumors

Journal of Immunological Methods

Volumn 241, Issue 1-2, 2000, Pages 61-68

  Zier, Karen ^a   Johnson, Kristen ^a   Maddux, Jean Marie ^a   Sung, Max ^a   Mandeli, John ^a   Eisenbach, Lea ^b   Schwartz, Myron ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

ELISPOT; Gene Therapy; Immune monitoring; Immunotherapy; T cells

Indexed keywords

GAMMA INTERFERON; GANCICLOVIR; THYMIDINE KINASE; TUMOR ANTIGEN; VIRUS VECTOR; PEPTIDE;

ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRATUMORAL DRUG ADMINISTRATION; LIVER METASTASIS; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TECHNIQUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; DOSE RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; METHODOLOGY; NEOPLASM; SECRETION;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LYMPHOCYTES; NEOPLASMS; PEPTIDES;

EID: 0034738173     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00193-9     Document Type: Article

References (25)

1. Boon T., Cerottini J.C., Van Der Byne B., Van Der Brugenn P., van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immun. 12:1994;337.
2. Boon T., Coulie P.G., van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 18:1997;267.
3. Chen S., Kosai K., Xu B., Pham-Nguyen K., Contant C., Finegold M., et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56:1996;3758.
4. Czerkinsky C., Anderson G., Ekre H.P., Nilsson L.A., Klareskog L., Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells. Immunol. Meth. 110:1988;29.
5. Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today. 20:1999;158.
6. Guarini A., Riera L., Cignetti A., Montacchini L., Massaia M., Foa R. Transfer of interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood. 89:1997;212.
7. Hagiwara B., Sacks T., Leitman-Klinman S.F., Klinman D.M. Effect of HIV infection on the frequency of cytokine-secreting cells in human peripheral blood. AIDS Res. Hum. Retroviruses. 12:1996;127.
8. + T lymphocytes secreting tumor necrosis factor α in response to HLAA2.1-binding melanoma and viral peptide antigens. J. Immunol. Meth. 191:1996;131.
9. Kiessling R., Kono K., Petersson M., Wasserman K. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin. Immunopathol. 18:1996;227.
10. + memory T cells. J. Exp. Med. 186:1997;859.
11. Lalvani A., Brookes R., Wilkinson R.J., et al. Human cytolytic and interferon γ-secreting CD8+ lymphocytes specific for Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 95:1998;270.
12. Larsson M., Jin X., Ramramam B., Ogg G., Engelmayer J., Demoitie M.-A., et al. A recombinant vaccina virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS. 13:1999;767.
13. Lee K.H., Wang E., Nielsen M.B., Wunderlich J., Migueles S., Connors M., Steinberg S.M., Rosenberg S.A., Marincola F.M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:1999;6292.
14. Mandelboim O., Berke G., Fridkin M., Feldman M., Eisenstein M., Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature. 369:1994;67.
15. Nair S.K., Boczkowski D., Snyder D., Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:1997;589.
16. + lymphocytes. Proc. Natl. Acad. Sci. USA. 96:1999;2982.
17. Pass H.A., Schwarz S.L., Wunderlich J.R., Rosenberg S.A. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Sci. Am. 4:1998;316.
18. Pittet M.J., Valmori D., Dunbar P.R., Speiser D.E., Lienard D., Lejeune F., et al. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:1999;705.
19. Salvadori S., Martinelli G., Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 164:1999;2214.
20. Scheibenbogen C., Lee K.-H., Mayer S., Stevanovic S., Moebius U., Herr W., et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:1997;221.
21. Scheibenbogen C., Lee K.-H., Stevanovic S., Witzens M., Willhauck M., Waldmann V., et al. Analysis of the T-cell response to tumor and viral peptide antigens by an IFN-gamma ELISPOT assay. Int. J. Cancer. 71:1997;932.
22. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Meth. 210:1997;167.
23. Sobota V., Bubenik J., Indrova M., Vlk V., Jakoubkova J. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients. J. Immunol. Meth. 203:1997;1.
24. Vile R., Nelson J., Castleden S., Chong H., Har I. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54:1994;6228.
25. Zier K., Gansbacher B., Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol. Today. 17:1996;39.